Cellipont Bioservices Names Brett Reynolds as New CFO
An experienced financial leader joins to support strategic growth and expansion goals.
Cellipont Bioservices, a leading cell therapy CDMO, has appointed Brett Reynolds as Chief Financial Officer (CFO), effective immediately. With over 25 years of financial leadership experience, primarily in the life sciences sector, Reynolds steps into the role following the retirement of Tim Heher.
Reynolds, a seasoned CFO with a proven track record in high-growth businesses, will oversee Cellipont’s financial strategy, IT operations, and support the company’s expansion plans. His expertise spans profitability enhancement, financial planning, M&A, and investor relations. “Brett’s experience makes him the ideal leader as we scale operations and innovate for our clients and their patients,” said Darren Head, CEO of Cellipont Bioservices. Reynolds expressed enthusiasm about contributing to Cellipont’s mission of advancing life-changing treatments.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Medicus Pharma soumet à la FDA le protocole de Phase 2b/3 pour Teverelix
Fresenius Kabi reçoit une lettre d’avertissement de la FDA après des défaillances d’enquête sur le traitement aseptique dans l’établissement de Melrose Park
Discussion